Article CRPI1 Mar 2021 21:52
The CEPI article dated 1/3/2021 says “For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses.”
Can we confirm SN14, is now superseded by SN15 and if so, is it being or had been manufactured for P1 trials?
Has the delivery mechanism now been approved ?